✦ LIBER ✦

Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer☆

✍ Scribed by John V Brown III; William A Peters III; Mark A Rettenmaier; Cheri L Graham; Michael R Smith; Charles W Drescher; John Paul Micha

Book ID: 114101307
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 66 KB
Volume: 88
Category: Article
ISSN: 0090-8258
DOI: 10.1016/s0090-8258(02)00021-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Three-Hour Paclitaxel Infusion and Carbo

Three-Hour Paclitaxel Infusion and Carboplatin Is an Effective Outpatient Treatment for Stage III Epithelial Ovarian Cancer

✍ John V. Brown; Mark A. Rettenmaier; Robert A. Dillman; Connie L. Birk; Kathleen 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Recurrent ovarian cancer: Is there a rol

Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?

✍ Georgia A. McCann; Blair Smith; Floor J. Backes; Kellie Rath; Simi Chacko; Ritu 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 378 KB

Plasminogen activator inhibitor-1 is an

Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients

✍ Setsuko K. Chambers; Christina M. Ivins; Maria L. Carcangiu 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 103 KB 👁 2 views

High levels of plasminogen activator inhibitor-1 (PAI-1) in tissue extracts have been associated with poor prognosis in many epithelial cancers. Ovarian cancers contain a higher concentration of PAI-1 than benign ovarian tumors or normal ovaries. Reports, however, on the prognostic value of PAI-1 co